CTRI/2009/091/000734招募中3 期
A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF CONTINUOUS POSITIVE AIRWAY PRESSURE IN MODERATE AND SEVERE ASTHMA
I0 个研究点目标入组 80 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a.Adults > 18 years of age
- •b.Known bronchial asthma patients
- •c.PEFR < 75% of expected value
- •d.RR > 25/min
- •e.Spo2 < 95%
排除标准
- •b.Pneumonia
- •c.Pleural effusion
- •d.Hemodynamicllay unstable (systolic BP < 90 mmHg, HR > 150/min)
- •e.Acute pulmonary oedema
- •f.Ischemic heart disease
- •g.Upper airway obstruction
- •h.Pregnancy
- •i.Facial deformity
- •j.Altered sensorium
研究者
相似试验
进行中（未招募）
不适用
A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND IMMUNOMODULATORY THERAPY FOR THE MANAGEMENT OF SEPSISEUCTR2006-004886-33-GRniversity of Athens, Medical school
进行中（未招募）
不适用
PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF BOSENTAN IN PATIENTS WITH INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION CTEPH .Treatment of the inoperable chronic thromboembolic pulmonary hypertensionMedDRA version: 6.1Level: PTClassification code 10037400EUCTR2005-001965-33-ITACTELION PHARMACEUTICALS ITALIA128
进行中（未招募）
1 期
BENEFIT OF CLARITHROMYCIN IN PATIENTS WITH SEVERE INFECTIONS THROUGH MODULATION OF THE IMMUNE SYSTEMIMMUNE MODULATION WITH CLARITHROMYCIN IN SEPSIS WITH MULTIPLE ORGAN AND RESPIRATORY DYSFUNCTIONMedDRA version: 20.0Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001056-55-GRHELLENIC INSTITUTE FOR THE STUDY OF SEPSIS110
进行中（未招募）
1 期
BENEFIT OF CLARITHROMYCIN IN PATIENTS WITH SEVERE INFECTIONS THROUGH MODULATION OF THE IMMUNE SYSTEMIMMUNE MODULATION WITH CLARITHROMYCIN IN SEPSIS WITH MULTIPLE ORGAN AND RESPIRATORY DYSFUNCTIONMedDRA version: 20.0 Level: PT Classification code 10040047 Term: Sepsis System Organ Class: 10021881 - Infections and infestationsEUCTR2017-001056-55-BEHELLENIC INSTITUTE FOR THE STUDY OF SEPSIS110
进行中（未招募）
不适用
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL CROSSOVER TRIAL IN ADULT ASTHMATICS EVALUATING THE EFFECT OF CONCOMITANT TWO WEEKS TREATMENT WITH MONTELUKAST (SINGULAIR™) 10 MG ONCE DAILY OR MATCHING PLACEBO TO PREVENT THE DEVELOPMENT OF TOLERANCE TO BRONCHOPROTECTION AND BRONCHODILATION BY BETA-AGONISTS OCCURRING AFTER TWO WEEKS REGULAR TREATMENT WITH SALMETEROL (SEREVENT™) 50µG B.I.D. - PREDATORIntermittend or mild asthma according to the definition of the Global Initiative ofor Asthma (GINA) guidelines step 1 or step 2 (2004)EUCTR2005-003991-39-DEinsaf, Institut für Atemwegsforschung GmbH20